In vitro biotransformation of dynorphin A (1-17) is similar in human and rhesus monkey blood as studied by matrix-assisted laser desorption/ionization mass spectrometry

Journal of Pharmacology and Experimental Therapeutics

Volumn 279, Issue 2, 1996, Pages 507-514

  Yu, Jim ^a   Butelman, Eduardo R ^b   Woods, James H ^b   Chait, Brian T ^a   Kreek, Mary Jeanne ^a  

^a ROCKEFELLER UNIVERSITY   (United States)

^b UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DYNORPHIN A; OPIATE PEPTIDE; TYROSINE;

ADULT; ANIMAL EXPERIMENT; ARTICLE; DRUG TRANSFORMATION; FEMALE; HUMAN; HUMAN EXPERIMENT; LASER; MALE; MASS SPECTROMETRY; MORPHINE TOLERANCE; NONHUMAN; NORMAL HUMAN; OPIATE ADDICTION; PRIORITY JOURNAL; RHESUS MONKEY; WITHDRAWAL SYNDROME;

ADULT; ANIMALS; BIOTRANSFORMATION; CALIBRATION; DYNORPHINS; FEMALE; HUMANS; MACACA MULATTA; MALE; MIDDLE AGED; SPECIES SPECIFICITY; SPECTROMETRY, MASS, MATRIX-ASSISTED LASER DESORPTION-IONIZATION; TEMPERATURE;

EID: 0030425573     PISSN: 00223565     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (33)

1. ACETO, M. D., DEWEY, W. L., CHANG, J. AND LEE, N. M.: Dynorphin-(1-13): Effects in nontolerant and morphine-dependent rhesus monkeys. Eur. J. Pharmacol. 83: 139-142, 1982.
2. BEAVIS, R. C. AND CHAIT, B. T.: Factors affecting the ultraviolet laser desorption of proteins. Rapid Commun. Mass Spectrom. 3: 233-237, 1989.
3. BEAVIS, R. C. AND CHAIT, B. T.: High-accuracy molecular mass determination of proteins using matrix-assisted laser desorption mass spectrometry. Anal. Chem. 62: 1836-1840, 1990.
4. BENUCK, M., BERG, M. J. AND MARKS, N.: Membrane-bound enzymes and their role in processing of the dynorphins and of the proenkephalin octapeptide met-enkephalin-Arg-Gly-Leu. Neurochem. Res. 9: 733-749, 1984.
5. BODNER, G., PINTO, S., ALBECK, H. AND KREEK, M. J.: The effects of dynorphin peptides on human natural killer cell activity in vitro. In Problems of Drug Dependence 1991: Proceedings of the 53rd Annual Scientific Meeting, The College on Problems of Drug Dependence, Inc., ed. by L. S. Harris, vol. 119, p. 331. NIDA Research Monograph Series, Washington, D.C.: Supt. of Docs., U.S. Govt. Print. Off., DHHS Pub. No. (ADM) 92-1888, 1992.
6. BUTELMAN, E. R., FRANCZ, C. P. AND WOODS, J. H.: Agonist and antagonist effects of dynorphin A (1-13) in a thermal antinociception assay in rhesus monkeys. J. Pharmacol. Exp. Ther. 275: 374-380, 1995.
7. CHOU, J. Z., PINTO, S., KREEK, M. J. AND CHAIT, B. T.: Study of opioid peptides by laser desorption mass spectrometry. In Problems of Drug Dependence 1992: Proceedings of the 54th Annual Scientific Meeting, The College on Problems of Drug Dependence, Inc., NIDA Research Monograph Series, vol. 132, p. 380, 1993.
8. CHOU, J. Z., KREEK, M. J. AND CHAIT, B. T.: Matrix-assisted laser desorption mass spectrometry of biotransformation products of dynorphin A in vitro. J. Am. Soc. Mass Spectrom. 5: 10-16, 1994.
9. 1-17. In Society for Neuroscience Abstracts of 24th Annual Meeting, Society for Neuroscience, Washington, D.C., vol. 20, p. 1738, 1994.
10. CLAYE, L. H., UNTERWALD, E. M., HO, A. AND KREEK, M. J.: Inhibition of adenylyl cyclase activity by opioid and non-opioid dynorphin A peptides in rat caudate putamen. In Problems of Drug Dependence 1995: Proceedings of the 57th Annual Scientific Meeting, The College on Problems of Drug Dependence, Inc., NIDA Research Monograph Series, Vol 162, p. 132, 1996a.
11. 2-17 inhibit adenylyl cyclase activity in rat caudate putamen. J. Pharmacol. Exp. Ther. 277: 359-365, 1996b.
12. DEVI, L. AND GOLDSTEIN, A.: Dynorphin converting enzyme with unusual specificity from rat brain. Proc. Natl. Acad. Sci. U.S.A. 81: 1892-1896, 1984.
13. DEVI, L., GUPTA, P. AND FRICKER, L. D.: Subcellular localization, partial purification, and characterization of a dynorphin processing endopeptidase from bovine pituitary. J. Neurochem. 56: 320-329, 1991.
14. FADEN, A. I.: Dynorphin increases extracellular levels of excitatory amino acids in the brain through a non-opioid mechanism. J. Neurosci. 12: 425-429, 1992.
15. GOLDSTEIN, A., TACHIBANA, S., LOWNEY, L. I., HUNKAPILLER, M. AND HOOD, L.: Dynorphin-(1-13), an extraordinarily potent opioid peptide. Proc. Natl. Acad. Sci. U.S.A. 76: 6666-6670, 1979.
16. 2-dynorphin-(1-11) in rats. Life Sci. 27: 883-892, 1980.
17. HOOKE, L. P., HE, L. AND LEE, N. M.: Dynorphin A modulates acute and chronic opioid effects. J. Pharmacol. Exp. Ther. 273: 802-807, 1995a.
18. 1] Dynorphin A-(2-17) has naloxone-insensitive antinociceptive effect in the writhing assay. J. Pharmacol. Exp. Ther. 273: 802-807, 1995b.
19. 1-13 administration causes elevation of serum levels of prolactin in human subjects. In Problems of Drug Dependence 1993: Proceedings of the 55th Annual Scientific Meeting, The College on Problems of Drug Dependence, Inc., ed. by L. S. Harris, vol. 141, p. 108. NIDA Research Monograph Series, Washington, D.C.: Supt. of Docs., U.S. Govt. Print. Off., NIH Pub. No. 94-3749, 1994.
20. LESLIE, F. AND GOLDSTEIN, A.: Degradation of dynorphin A (1-13) by membrane-bound rat brain enzymes. Neuropeptides 2: 185-196, 1982.
21. MAISONNEUVE, I. M. AND KREEK, M. J.: Acute tolerance to the dopamine response induced by a binge pattern of cocaine administration in male rats: an in vivo microdialysis study. J. Pharmacol. Exp. Ther. 268: 916-921, 1994.
22. NYBERG, F., NORDSTROM, K. AND TERENIUS, L.: Endopeptidase in human cerebrospinal fluid which cleaves proenkephalin B opioid peptides at consecutive basic amino acids. Biochem. Biophys. Res. Commun. 131: 1069-1074, 1985.
23. PETANCESKA, S., ZIKHERMAN, J., FRICKER, L. D. AND DEVI, L.: Processing of prodynorphin in BRL-3A cells, a rat liver-derived cell line: implications for the specificity of neuropeptide-processing enzymes. Mol. Cell Endocrinol. 94: 37-45, 1993.
24. SILBERRING, J., CASTELLO, M. E. AND NYBERG, F.: Characterization of dynorphin A-converting enzyme in human spinal cord. J. Biol. Chem. 267: 21324-21328, 1992.
25. SMITH, A. P. AND LEE, N. M.: Pharmacology of dynorphin. Annu. Rev. Pharmacol. Toxicol. 28: 123-140, 1988.
26. SPANGLER, R., UNTERWALD, E. M. AND KREEK, M. J.: 'Binge' cocaine administration induces a sustained increase of prodynorphin mRNA in rat caudate-putamen. Mol. Brain Res. 19: 323-327, 1993.
27. SPANGLER, R., ZHOU, Y., UNTERWALD, E. M., YUFEROV, V., HO, A. AND KREEK, M. J.: Kappa opioid receptor mRNA levels in the rat brain: effects of dopamine antagonists and cocaine. In Regulatory Peptides, ed. by E. J. Simon, vol. 54, pp. 283, Elsevier, Amsterdam, 1994.
28. SPANGLER, R., HO, A., ZHOU, Y., MAGGOS, C., YUFEROV, V. AND KREEK, M. J.: Regulation of kappa opioid receptor mRNA in the rat brain by "binge" pattern cocaine administration and correlation with preprodynorphin mRNA. Mol Brain Res. 38: 71-76, 1996.
29. TAKEMORI, A. E., LOH, H. H. AND LEE, N. M.: Suppression by dynorphin A-(1-13) of the expression of opiate withdrawal and tolerance in mice. Eur. J. Pharmacol. 221: 223-226, 1992.
30. 1]dynorphin A peptides of the expression of opiate withdrawal and tolerance in morphine-dependent mice. J. Pharmacol. Exp. Ther. 266: 121-124, 1993.
31. 1-13 in the mouse and rat: Initial observations. Peptides 1: 341-345, 1980.
32. WALKER, J. M., MOISES, H. C., COY, D. H., BALDRIGHI, G. AND AKIL, H.: Nonopiate effects of dynorphin and des-Tyr-dynorphin. Science 218: 1136-1138, 1982.
33. YOUNG, E. A., WALKER, J. M., HOUGHTEN, R. AND AKIL, H.: The degradation of dynorphin A in brain tissue in vivo and in vitro. Peptides 8: 701-707, 1987.